<!DOCTYPE html>
<html>
<head>
  <meta charset="utf-8">

  <!-- PACE Progress Bar START -->
  
    
<script src="https://raw.githubusercontent.com/HubSpot/pace/v1.0.2/pace.min.js"></script>

    
<link rel="stylesheet" href="https://github.com/HubSpot/pace/raw/master/themes/orange/pace-theme-flash.css">

  
  

  <!-- PACE Progress Bar START -->

  
  <title>Yujie&#39;s Blog</title>
  <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">
  
  
  
  
  <meta name="description" content="文章来源： 《经济学人》Jun 19th 2021 期 Science &amp; technology 栏目   A new weapon in the war against SARS-CoV-2 has been found抗击SARS-CoV-2的新手段被发现 Antibody of evidence证据抗体 ![image-20210620103932225](&#x2F;Users&amp;#">
<meta property="og:type" content="article">
<meta property="og:title" content="Yujie&#39;s Blog">
<meta property="og:url" content="http://example.com/2021/06/20/Day425-The%20Economist/index.html">
<meta property="og:site_name" content="Yujie&#39;s Blog">
<meta property="og:description" content="文章来源： 《经济学人》Jun 19th 2021 期 Science &amp; technology 栏目   A new weapon in the war against SARS-CoV-2 has been found抗击SARS-CoV-2的新手段被发现 Antibody of evidence证据抗体 ![image-20210620103932225](&#x2F;Users&amp;#">
<meta property="og:locale">
<meta property="article:published_time" content="2021-06-20T02:38:24.579Z">
<meta property="article:modified_time" content="2021-06-20T02:39:33.657Z">
<meta property="article:author" content="Chen Yujie">
<meta name="twitter:card" content="summary">
  
    <link rel="alternate" href="/atom.xml" title="Yujie&#39;s Blog" type="application/atom+xml">
  
  <link rel="icon" href="/css/images/favicon.ico">
  
    <link href="//fonts.googleapis.com/css?family=Source+Code+Pro" rel="stylesheet" type="text/css">
  
  <link href="https://fonts.googleapis.com/css?family=Open+Sans|Montserrat:700" rel="stylesheet" type="text/css">
  <link href="https://fonts.googleapis.com/css?family=Roboto:400,300,300italic,400italic" rel="stylesheet" type="text/css">
  <link href="https://cdn.bootcss.com/font-awesome/4.6.3/css/font-awesome.min.css" rel="stylesheet">
  <style type="text/css">
    @font-face{font-family:futura-pt;src:url(https://use.typekit.net/af/9749f0/00000000000000000001008f/27/l?subset_id=2&fvd=n5) format("woff2");font-weight:500;font-style:normal;}
    @font-face{font-family:futura-pt;src:url(https://use.typekit.net/af/90cf9f/000000000000000000010091/27/l?subset_id=2&fvd=n7) format("woff2");font-weight:500;font-style:normal;}
    @font-face{font-family:futura-pt;src:url(https://use.typekit.net/af/8a5494/000000000000000000013365/27/l?subset_id=2&fvd=n4) format("woff2");font-weight:lighter;font-style:normal;}
    @font-face{font-family:futura-pt;src:url(https://use.typekit.net/af/d337d8/000000000000000000010095/27/l?subset_id=2&fvd=i4) format("woff2");font-weight:400;font-style:italic;}</style>
    
  <link rel="stylesheet" id="athemes-headings-fonts-css" href="//fonts.googleapis.com/css?family=Yanone+Kaffeesatz%3A200%2C300%2C400%2C700&amp;ver=4.6.1" type="text/css" media="all">
  
<link rel="stylesheet" href="/css/style.css">


  
<script src="https://code.jquery.com/jquery-3.1.1.min.js"></script>


  <!-- Bootstrap core CSS -->
  <link rel="stylesheet" href="https://netdna.bootstrapcdn.com/bootstrap/3.0.2/css/bootstrap.min.css" >
  <link rel="stylesheet" href="/css/hiero.css" >
  <link rel="stylesheet" href="/css/glyphs.css" >
  
    <link rel="stylesheet" href="/css/vdonate.css" >
  

  <!-- Custom CSS -->
  
<link rel="stylesheet" href="/css/my.css">

  <!-- Google Adsense -->
  
  <script async src="//pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script>
  <script>
      (adsbygoogle = window.adsbygoogle || []).push({
          google_ad_client: "ca-pub-0123456789ABCDEF",
          enable_page_level_ads: true
      });
  </script>
  
<meta name="generator" content="Hexo 6.3.0"></head>

<script>
var themeMenus = {};

  themeMenus["/"] = "Home"; 

  themeMenus["/archives"] = "Archives"; 

  themeMenus["/categories"] = "Categories"; 

  themeMenus["/tags"] = "Tags"; 

  themeMenus["/about"] = "About"; 

</script>


  <body data-spy="scroll" data-target="#toc" data-offset="50">


  <header id="allheader" class="site-header" role="banner">
  <div class="clearfix container">
      <div class="site-branding">

          <h1 class="site-title">
            
              <a href="/" title="Yujie&#39;s Blog" rel="home"> Yujie&#39;s Blog </a>
            
          </h1>

          
            <div class="site-description">Welcome to my channel</div>
          
            
          <nav id="main-navigation" class="main-navigation" role="navigation">
            <a class="nav-open">Menu</a>
            <a class="nav-close">Close</a>
            <div class="clearfix sf-menu">

              <ul id="main-nav" class="nmenu sf-js-enabled">
                    
                      <li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-home menu-item-1663"> <a class="" href="/">Home</a> </li>
                    
                      <li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-home menu-item-1663"> <a class="" href="/archives">Archives</a> </li>
                    
                      <li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-home menu-item-1663"> <a class="" href="/categories">Categories</a> </li>
                    
                      <li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-home menu-item-1663"> <a class="" href="/tags">Tags</a> </li>
                    
                      <li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-home menu-item-1663"> <a class="" href="/about">About</a> </li>
                    
              </ul>
            </div>
          </nav>


      </div>
  </div>
</header>


  <div id="originBgDiv" style="background: #fff; width: 100%;">

      <div style="max-height:600px; overflow: hidden;  display: flex; display: -webkit-flex; align-items: center;">
        <img id="originBg" width="100%" alt="" src="">
      </div>

  </div>

  <script>
  function setAboutIMG(){
      var imgUrls = "css/images/pose.jpg,https://source.unsplash.com/collection/954550/1920x1080".split(",");
      var random = Math.floor((Math.random() * imgUrls.length ));
      if (imgUrls[random].startsWith('http') || imgUrls[random].indexOf('://') >= 0) {
        document.getElementById("originBg").src=imgUrls[random];
      } else {
        document.getElementById("originBg").src='/' + imgUrls[random];
      }
  }
  bgDiv=document.getElementById("originBgDiv");
  if(location.pathname.match('about')){
    setAboutIMG();
    bgDiv.style.display='block';
  }else{
    bgDiv.style.display='none';
  }
  </script>



  <div id="container">
    <div id="wrap">
            
      <div id="content" class="outer">
        
          <section id="main" style="float:none;"><article id="post-Day425-The Economist" style="width: 66%; float:left;" class="article article-type-post" itemscope itemprop="blogPost" >
  <div id="articleInner" class="clearfix post-1016 post type-post status-publish format-standard has-post-thumbnail hentry category-template-2 category-uncategorized tag-codex tag-edge-case tag-featured-image tag-image tag-template">
    
    
    <div class="article-meta">
      
	Posted on <a href="/2021/06/20/Day425-The%20Economist/" class="article-date">
	  <time datetime="2021-06-20T02:38:24.579Z" itemprop="datePublished">June 20, 2021</time>
	</a>

      
	<span id="busuanzi_container_page_pv">
	  本文总阅读量<span id="busuanzi_value_page_pv"></span>次
	</span>

    </div>
    <div class="article-entry" itemprop="articleBody">
      
        <p>文章来源： 《经济学人》Jun 19th 2021 期 Science &amp; technology 栏目  </p>
<h1 id="A-new-weapon-in-the-war-against-SARS-CoV-2-has-been-found"><a href="#A-new-weapon-in-the-war-against-SARS-CoV-2-has-been-found" class="headerlink" title="A new weapon in the war against SARS-CoV-2 has been found"></a>A new weapon in the war against SARS-CoV-2 has been found</h1><p>抗击SARS-CoV-2的新手段被发现</p>
<h6 id="Antibody-of-evidence"><a href="#Antibody-of-evidence" class="headerlink" title="Antibody of evidence"></a>Antibody of evidence</h6><p>证据抗体</p>
<p>![image-20210620103932225](&#x2F;Users&#x2F;chenyujie&#x2F;Library&#x2F;Application Support&#x2F;typora-user-images&#x2F;image-20210620103932225.png)</p>
<h5 id="It-is-expensive-though-and-in-short-supply"><a href="#It-is-expensive-though-and-in-short-supply" class="headerlink" title="It is expensive, though, and in short supply"></a>It is expensive, though, and in short supply</h5><p>尽管价格昂贵，而且供应不足</p>
<blockquote>
<p>Jun 16th 2021 </p>
</blockquote>
<p>AN ANTIBODY THERAPY from Regeneron, a firm in upstate New York, improves the survival of patients with covid-19 and <strong>offers renewed hope</strong> for the treatment of <strong>those most seriously ill</strong> with the disease. A study in British hospitals found that Regen-Cov <strong>saved the lives</strong> of many of those unable to make their own antibodies in response to SARS-CoV-2. Such “seronegative” individuals constituted about a third of the 9,785 hospital patients in the study. As compared with a control group given standard treatment (either a steroid called dexamethasone or, for the sickest, an anti-inflammatory known as tocilizumab), 20% more patients survived. Regen-Cov also reduced the median length of hospital stays from 17 to 13 days.</p>
<blockquote>
<p>constitute 构成；成为</p>
</blockquote>
<p>纽约州边远地区的Regeneron公司推出的抗体疗法提高了covid-19患者的存活率，并为治疗最严重的covid-19患者带来了新的希望。英国医院的一项研究发现，Regen-Cov挽救了许多无法产生自身抗体来应对SARS-CoV-2的患者的生命。这类“血清阴性”的个体在9785名研究中的医院病人中占了大约三分之一。与接受标准治疗(类固醇地塞米松或对病情最严重的患者使用消炎药托珠单抗)的对照组相比，存活率增加了20%。Regen-Cov还将平均住院时间从17天缩短到13天。</p>
<p>Regen-Cov is a combination of two monoclonal antibodies, known as casirivimab and imdevimab. Antibodies are immune-system proteins that <strong>disable pathogens</strong> by locking specifically onto them. Both casirivimab and imdevimab bind to different sites on the coronavirus’s “spike” protein, preventing the virus from infecting cells. Using two antibodies instead of one <strong>reduces the risk of the virus evolving resistance to the treatment.</strong></p>
<p>Regen-Cov是两种单克隆抗体的组合，称为casirivimab和imdevimab。抗体是一种免疫系统蛋白质，通过特异性地锁定病原体使其失效。casirivimab和imdevimab都能结合冠状病毒“刺突”蛋白的不同位点，防止病毒感染细胞。使用两种而非一种抗体，可以降低病毒对治疗产生耐药性的风险。</p>
<p>Until now,  trials have not <strong>made a convincing case</strong> for the widespread use of antibody therapies for covid-19. One problem has been a failure to identify a clear group of patients who can <strong>benefit from these costly treatments</strong>. This is the first study large enough to show that such a therapy reduces mortality in patients admitted to hospital with severe covid-19. A year ago, the same Recovery trial run by British scientists also discovered that dexamethasone would save patients’ lives.</p>
<p>到目前为止，试验还没有提供令人信服的证据可以证明广泛使用抗体疗法治疗covid-19。其中一个问题是，未能明确确定哪些患者可以从这些昂贵的治疗中获益。这是首次有足够大的研究表明，这种疗法可以降低因严重covid-19住院患者的死亡率。一年前，英国科学家进行的同样的康复试验也发现地塞米松可以挽救病人的生命。</p>
<p>Regen-Cov already <strong>has emergency authorisation for use</strong> in America, Brazil, Canada, the European Union and India, but <strong>remains an investigational drug</strong> in Britain and elsewhere. Even if authorisation follows in many other countries, though, access to it is likely to remain extremely restricted.</p>
<p>Regen-Cov已经获得美国、巴西、加拿大、欧盟和印度的紧急批准，但在英国和其他地方仍是一种研究药物。然而，即使在其他许多国家也获得了授权，获取它的途径可能仍然受到极大限制。</p>
<p>![image-20210620103859367](&#x2F;Users&#x2F;chenyujie&#x2F;Library&#x2F;Application Support&#x2F;typora-user-images&#x2F;image-20210620103859367.png) </p>
<p>Soumya Swaminathan, the chief scientist at the World Health Organisation, said <strong>the result was good news</strong>, but warned that <strong>access to monoclonal-antibody drugs was “limited globally”.</strong> A recent study by the Wellcome Trust, a British medical charity, and IAVI, the International AIDS Vaccine Initiative, showed just <strong>how unavailable these drugs are in various parts of the world</strong> (see chart). More than three-quarters of the market for them is in America, Canada and Europe. So far, two countries, America and Germany, have bought large supplies of Regen-Cov. In January, America agreed to purchase up to 1.25m doses for $2.6bn. In the same month, Germany spent $487m on 200,000 doses. (Donald Trump was treated with Regen-Cov when he fell ill with covid-19.)</p>
<blockquote>
<p>unavailable 无法得到的</p>
</blockquote>
<p>世界卫生组织首席科学家Soumya Swaminathan表示，这一结果是好消息，但他警告称，单克隆抗体药物的获得“在全球范围内是有限的”。英国医疗慈善机构Wellcome Trust和国际艾滋病疫苗倡议组织(IAVI)最近的一项研究显示，这些药物在世界各地是多么难获得(见图表)。超过四分之三的市场在美国、加拿大和欧洲。到目前为止，美国和德国这两个国家已经购买了大量的Regen-Cov。今年1月，美国同意以26亿美元购买至多125万剂疫苗。同月，德国花费4.87亿美元购买了20万剂疫苗。(特朗普在感染covid-19时接受了Regen-Cov治疗。)</p>
<p><strong>The reasons for this geographical concentration are twofold but related</strong>: quantity and price. Production facilities for monoclonal-antibody therapies are few. And, in general, only wealthy countries can afford them. Regen-Cov costs many thousands of dollars a dose.</p>
<p>这种地理上集中的原因虽有两个方面，但它们是相关的:数量和价格。用于单克隆抗体治疗的生产设施很少。而且，一般来说，只有富裕国家才能负担得起。Regen-Cov每剂要花费数千美元。</p>
<p>Dr Swaminathan says <strong>more monoclonal-antibody factories need to be established around the world</strong> so that such treatments become accessible and affordable. <strong>Lack of availability of Regen-Cov will probably become a topic of interest</strong> to those who argue that intellectual property in covid-19-related technologies should be waived by the World Trade Organisation.</p>
<p>Swaminathan博士说，需要在世界各地建立更多的单克隆抗体工厂，这种治疗从而就会变得容易获得和负担得起。Regen-Cov的缺乏可能会成为一些人感兴趣的话题，他们认为世界贸易组织应该放弃与covid-19相关的技术的知识产权。</p>
<p>So far, trials for covid-19 antibody-therapies have generally been disappointing, but <strong>news of Regen-Cov’s success is likely to reinvigorate interest in them.</strong> Eli Lilly’s antibody therapy, LY-CoV555, <strong>failed to provide benefit to hospital patients</strong> in a trial reported last December, while on June 15th <strong>a similar drug from AstraZeneca also disappointed</strong> when given to those who had been exposed to the virus. <strong>These drugs might, however, turn out to be beneficial</strong> if they are given to the narrower patient group identified by the Recovery trial.</p>
<blockquote>
<p>reinvigorate 使..精神焕发；给..注入新的活力</p>
</blockquote>
<p>到目前为止，covid-19抗体疗法的试验总是令人失望，但Regen-Cov成功的消息可能会重新激发人们对这些疗法的兴趣。在去年12月报道的一项临床试验中，Eli Lilly公司的抗体疗法LY-CoV555未能给住院患者带来好处，而在6月15日，阿斯利康公司的一种类似药物在给那些接触过病毒的患者使用后，其结果也令人失望。然而，如果将这些药物用于康复试验中确定的范围较小的患者群体，它们可能会带来益处。</p>
<p><strong>Should demand for Regen-Cov now increase, though, it is not clear how quickly supply could be improved</strong>—even in countries that have the money to pay for it. Monoclonal-antibody production lines are currently used to make cancer and arthritis drugs, which are also badly needed. Moreover, supplies of much of the equipment required, including biobags (giant disposable plastic bags used to make drugs), filters and sterilisation gear, are already <strong>stretched thin</strong> by demands from vaccine manufacturers. Earlier this year, two pharma companies complained that <strong>their ability to make monoclonal antibodies was hampered</strong> by shortages of equipment, thanks to the global push to make vaccines.</p>
<blockquote>
<p> arthritis 关节炎</p>
</blockquote>
<p>不过，如果现在对Regen-Cov的需求增加，即使是在有资金购买的国家，供应速度能提高多快也尚不清楚。单克隆抗体生产线目前被用于生产癌症和关节炎药物，这些药物也是迫切需要的。此外，由于疫苗制造商的需求，包括生物袋(用于生产药品的巨大一次性塑料袋)、过滤器和消毒设备在内的许多所需设备的供应已经捉襟见肘。今年早些时候，两家制药公司抱怨说，由于全球推动疫苗生产，设备短缺阻碍了他们生产单克隆抗体的能力。</p>
<p><strong>Any attempt to increase the supply of monoclonal antibodies in coming months could thus compete with vaccine manufacturing.</strong> America currently <strong>has a lock on much of the supply of equipment and raw materials</strong> needed to make vaccines, a hold it maintains through the use of the Defence Production Act. If America chose to use the DPA to support monoclonal antibody production, that might <strong>have an impact on vaccine production in countries</strong> such as Brazil, Britain and India.</p>
<p>因此，任何在未来几个月增加单克隆抗体供应的尝试都可能与疫苗生产相竞争。美国目前对疫苗生产所需的设备和原材料的供应有很大的限制，这一限制是通过《国防生产法案》维持的。如果美国选择使用《国防生产法案》来支持单克隆抗体的生产，这可能会对巴西、英国和印度等国的疫苗生产产生影响。</p>
<p>The Recovery study also seems to <strong>settle a scientific debate</strong> about whether it is worth giving antiviral therapies to covid-19 patients when they arrive in hospital. It is. It had been thought that, by the time a patient arrived, only anti-inflammatory drugs, which treat damage already done by the virus, were relevant. <strong>Knowledge</strong> that patients who are seronegative are able to benefit from antiviral therapies <strong>opens up further lines of investigation for antiviral drugs.</strong> In the Recovery trial, untreated seronegative patients were twice as likely to die as those who were able to mount an antibody response.</p>
<p>康复研究似乎还解决了一场科学辩论，即是否值得在covid-19患者入院时给予抗病毒治疗。它是值得的。人们一直认为，当病人入院时，只有治疗病毒已经造成的损害的消炎药才是有意义的。了解到血清阴性的患者可以从抗病毒治疗中获益，这为抗病毒药物的进一步研究开辟了道路。在康复试验中，未接受治疗的血清阴性患者的死亡率是那些能够产生抗体反应的患者的两倍。</p>
<p>For doctors, <strong>the trial raises an intriguing question.</strong> If they have patients languishing at home with covid-19, might it be worth offering a cheap lateral flow test to try to identify those who are not mounting an immune response? If it is possible to spot those most likely to end up in hospital, and stop that happening, it would help to weaken the virus’s hold on patients, and on society at large.</p>
<p>对医生来说，这次试验提出了一个有趣的问题。如果他们有患者在家里受covid-19困扰，是否值得提供一种廉价的横向血流测试，以试图确定哪些人没有产生免疫反应? 如果能够发现最有可能住院的人，并阻止这种情况发生，这将有助于削弱病毒对患者和整个社会的控制。</p>

      
    </div>
    <footer class="entry-meta entry-footer">
      
      
      
        <div id="donation_div"></div>


<script src="/js/vdonate.js"></script>

<script>
var a = new Donate({
  title: '如果觉得我的文章对您有用，请随意打赏。您的支持将鼓励我继续创作!', // 可选参数，打赏标题
  btnText: 'Donate', // 可选参数，打赏按钮文字
  el: document.getElementById('donation_div'),
  wechatImage: 'https://raw.githubusercontent.com/iTimeTraveler/iTimeTraveler.github.io/site/source/about/donate/images/WeChanQR.png',
  alipayImage: 'https://raw.githubusercontent.com/iTimeTraveler/iTimeTraveler.github.io/site/source/about/donate/images/AliPayQR.jpg'
});
</script>
      
            
      
        
	<div id="comment">
		<!-- 来必力City版安装代码 -->
		<div id="lv-container" data-id="city" data-uid="MTAyMC8yOTQ4MS82MDQ5">
		<script type="text/javascript">
		   (function(d, s) {
		       var j, e = d.getElementsByTagName(s)[0];

		       if (typeof LivereTower === 'function') { return; }

		       j = d.createElement(s);
		       j.src = 'https://cdn-city.livere.com/js/embed.dist.js';
		       j.async = true;

		       e.parentNode.insertBefore(j, e);
		   })(document, 'script');
		</script>
		<noscript>为正常使用来必力评论功能请激活JavaScript</noscript>
		</div>
		<!-- City版安装代码已完成 -->
	</div>


      
    </footer>
  </div>
  
    
<nav id="article-nav">
  
    <a href="/2021/06/21/Day426-The%20Economist/" id="article-nav-newer" class="article-nav-link-wrap">
      <strong class="article-nav-caption">Newer</strong>
      <div class="article-nav-title">
        
          (no title)
        
      </div>
    </a>
  
  
    <a href="/2021/06/19/Day424-The%20Economist/" id="article-nav-older" class="article-nav-link-wrap">
      <strong class="article-nav-caption">Older</strong>
      <div class="article-nav-title"></div>
    </a>
  
</nav>

  
</article>

<!-- Table of Contents -->

  <aside id="sidebar">
    <div id="toc" class="toc-article" style="overflow-y: scroll; max-width: 28%;">
    <strong class="toc-title">Contents</strong>
    
      <ol class="nav"><li class="nav-item nav-level-1"><a class="nav-link" href="#A-new-weapon-in-the-war-against-SARS-CoV-2-has-been-found"><span class="nav-number">1.</span> <span class="nav-text">A new weapon in the war against SARS-CoV-2 has been found</span></a><ol class="nav-child"><li class="nav-item nav-level-6"><a class="nav-link" href="#Antibody-of-evidence"><span class="nav-number">1.0.0.0.0.1.</span> <span class="nav-text">Antibody of evidence</span></a></li></ol></li><li class="nav-item nav-level-5"><a class="nav-link" href="#It-is-expensive-though-and-in-short-supply"><span class="nav-number">1.0.0.0.1.</span> <span class="nav-text">It is expensive, though, and in short supply</span></a></li></ol></li></ol></li></ol></li></ol></li></ol>
    
    </div>
  </aside>
</section>
        
      </div>
      <footer id="footer" class="site-footer">
  

  <div class="clearfix container">
      <div class="site-info">
	      &copy; 2023 Yujie&#39;s Blog All Rights Reserved.
          
            <span id="busuanzi_container_site_uv">
              本站访客数<span id="busuanzi_value_site_uv"></span>人次  
              本站总访问量<span id="busuanzi_value_site_pv"></span>次
            </span>
          
      </div>
      <div class="site-credit">
        Theme by <a href="https://github.com/iTimeTraveler/hexo-theme-hiero" target="_blank">hiero</a>
      </div>
  </div>
</footer>


<!-- min height -->

<script>
    var contentdiv = document.getElementById("content");

    contentdiv.style.minHeight = document.body.offsetHeight - document.getElementById("allheader").offsetHeight - document.getElementById("footer").offsetHeight + "px";
</script>

<!-- Custome JS -->

<script src="/js/my.js"></script>

    </div>
    <!-- <nav id="mobile-nav">
  
    <a href="/" class="mobile-nav-link">Home</a>
  
    <a href="/archives" class="mobile-nav-link">Archives</a>
  
    <a href="/categories" class="mobile-nav-link">Categories</a>
  
    <a href="/tags" class="mobile-nav-link">Tags</a>
  
    <a href="/about" class="mobile-nav-link">About</a>
  
</nav> -->
    

<!-- mathjax config similar to math.stackexchange -->

<script type="text/x-mathjax-config">
  MathJax.Hub.Config({
    tex2jax: {
      inlineMath: [ ['$','$'], ["\\(","\\)"] ],
      processEscapes: true
    }
  });
</script>

<script type="text/x-mathjax-config">
    MathJax.Hub.Config({
      tex2jax: {
        skipTags: ['script', 'noscript', 'style', 'textarea', 'pre', 'code']
      }
    });
</script>

<script type="text/x-mathjax-config">
    MathJax.Hub.Queue(function() {
        var all = MathJax.Hub.getAllJax(), i;
        for(i=0; i < all.length; i += 1) {
            all[i].SourceElement().parentNode.className += ' has-jax';
        }
    });
</script>

<script type="text/javascript" src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.4/MathJax.js?config=TeX-AMS-MML_HTMLorMML">
</script>



  
<link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/fancybox/2.1.5/jquery.fancybox.min.css">

  
<script src="https://cdnjs.cloudflare.com/ajax/libs/fancybox/2.1.5/jquery.fancybox.min.js"></script>




<script src="/js/scripts.js"></script>


<script src="https://stackpath.bootstrapcdn.com/bootstrap/3.3.7/js/bootstrap.min.js"></script>


<script src="/js/main.js"></script>








  <div style="display: none;">
    <script src="https://s95.cnzz.com/z_stat.php?id=1260716016&web_id=1260716016" language="JavaScript"></script>
  </div>



	<script async src="https://dnqof95d40fo6.cloudfront.net/atw7f8.js">
	</script>






  </div>

  <a id="rocket" href="#top" class=""></a>
  <script type="text/javascript" src="/js/totop.js" async=""></script>
</body>
</html>
